



# NOCA

National Ovarian  
Cancer Audit

NOCA, Clinical Effectiveness Unit

Royal College of Surgeons of England  
38-43 Lincoln's Inn Fields  
London WC2A 3PE

E: [OvarianCancerAudit@rcseng.ac.uk](mailto:OvarianCancerAudit@rcseng.ac.uk)

T: 020 7869 6606

 [NOCA\\_NATCAN](https://twitter.com/NOCA_NATCAN)

## NOCA Newsletter, Autumn 2023

### Want to hear more?

The NOCA is part of the National Cancer Audit Collaborating Centre (NATCAN). If you want to find out more about NATCAN visit our [new website](#). If you would like to receive regular updates send us an email [NATCAN@rcseng.ac.uk](mailto:NATCAN@rcseng.ac.uk)



### Introducing our Clinical Fellow!

We are delighted to welcome Dr Georgia Zachou to the NOCA Project Team. Georgia is an Obstetrics and Gynaecology trainee based in North Central and East London. Alongside her audit responsibilities, she plans to undertake a PhD in ovarian cancer at the London School of Hygiene & Tropical Medicine. In addition, she aspires to pursue further clinical training in Gynaecological Oncology Surgery.

Georgia says, "I am really excited about being part of the NOCA team and actively working towards enhancing outcomes for women diagnosed with ovarian cancer."

### First Clinical Reference Group – audit scoping

The NOCA Clinical Reference Group held its first meeting in September 2023; top of the agenda was the scope of the audit. The NOCA Project Team worked closely with stakeholders including NHS England, Public Health Wales, Ovarian Cancer Action, Target Ovarian Cancer and the British Gynaecological Cancer Society, to produce a scoping document which will be published in November on the [NOCA website](#). This document outlines the 5 Quality Improvement goals that NOCA will focus on and will provide a basis for the NOCA Healthcare Improvement Strategy, which is planned for the first quarter of 2024, and will include detail on the quality performance indicators.

Also coming up in the first quarter of 2024 will be our first NOCA webinar where we will present initial analysis on the data. More details to come!

### How are patient data being collected?

The audits in NATCAN, similar to the existing audits in prostate and lung cancer, do not 'collect' clinical data. The cancer audits utilise the nationally mandated flows of data from hospitals to the National Disease Registration Service (NDRS) in NHSE and the Wales Cancer Network in Public Health Wales. Each NATCAN audit will publish a minimum dataset in the Autumn of 2023, comprising relevant data items for each cancer site, which hospitals can check are being completed and submitted to NDRS or the Wales Cancer Network.

Therefore, there is no need for NHS organisations to formally register for the audits, or input data on patients through a separate database portal. Additionally, there is no audit specific deadline for sites to submit the data.

